<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307461</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-15</org_study_id>
    <nct_id>NCT02307461</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145</brief_title>
  <official_title>A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Evaluate the Bioequivalence of the two formulations of IPI-145 and the Effect of Food on
      the Pharmacokinetics of IPI-145
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1, randomized, open-label study of IPI-145 will be conducted in 2 parts.

      Part 1 will be conducted in 2 cohorts. Cohort 1 will consist of 32 healthy subjects, and
      Cohort 2 will consist of 52 healthy subjects. Subjects in each cohort will receive 2 doses of
      IPI under fasted conditions in a 2-period, 2-sequence crossover design. Dosing in Period 1
      and Period 2 will be separated by at least 7 days.

      Part 2 is a 2-period, 2-sequence crossover design to assess the effect of a high-fat meal on
      the PK of the IPI-145 in 20 subjects. Subjects will receive single oral doses under fed
      (high-fat meal) and fasted conditions, separated by at least 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of bioequivalence of the IPI-145 test and reference formulations</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter (AUClast ) of IPI-145</measure>
    <time_frame>Over 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter (AUCinf ) of IPI-145</measure>
    <time_frame>Over 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter (Cmax) of IPI-145</measure>
    <time_frame>Over 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events following administration of IPI-145</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145 (duvelisib)</intervention_name>
    <description>High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145</intervention_name>
    <description>Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose</description>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145</intervention_name>
    <description>High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food</description>
    <arm_group_label>Part 2 Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women of non-child bearing potential between 18-50 years of age

          -  Body Mass Index (BMI): 18.0 - 32.0 kg/m2.

          -  Healthy subjects: in good health, determined by no clinically significant findings
             from clinical evaluations

          -  Provided written informed consent prior to any study specific procedures

        Exclusion Criteria:

          -  Women of childbearing potential

          -  Healthy subjects: positive screening test for hepatitis B surface antigen, hepatitis C
             antibody, or HIV-1/HIV-2 antibodies

          -  ECG at screening showing QTcF â‰¥ 450 msec

          -  Evidence of clinically significant medical conditions

          -  History of gastrointestinal disease or surgery that may affect drug absorption

          -  Positive T-Spot (tuberculosis)TB test at screening

          -  Any active infection at the time of screening or admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Dickerson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA International, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Food</keyword>
  <keyword>Healthy Adult</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

